NCT07441408

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 2,277 (estimated)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).

Conditions

• Pulmonary Fibrosis

Interventions

Type	Name	Description
DRUG	BMS-986278	Specified dose on specified days

Timeline

• Start date: 2026-12-16
• Primary completion: 2029-11-22
• Completion: 2030-03-30
• First posted: 2026-03-02
• Last updated: 2026-04-06

Locations

162 sites across 21 countries: Argentina, Australia, Belgium, Canada, Chile, Colombia, Denmark, Finland, France, India, Ireland, Italy, Japan, Mexico, Netherlands, Peru, Portugal, South Korea, Spain, Taiwan, United Kingdom

Regulatory

• FDA-regulated drug study